The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
16 | 10 | 42 | 37 |
Growth
|
59 | 97 | 25 | 61 |
Safety
|
86 | 1 | 100 | 100 |
Sentiment
|
89 | 72 | 18 | 25 |
|
89 | 54 | 11 | 31 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
71 | 71 | 3 | 31 |
Opinions Change
|
50 | 50 | 95 | 9 |
Pro Holdings
|
n/a | 58 | 1 | 43 |
Market Pulse
|
82 | 52 | 55 | 94 |
Sentiment
|
89 | 72 | 18 | 25 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
16 | 10 | 42 | 37 |
Growth
|
59 | 97 | 25 | 61 |
|
86 | 1 | 100 | 100 |
Combined
|
61 | 14 | 23 | 23 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
20 | 23 | 1 | 24 |
Price vs. Earnings (P/E)
|
81 | 64 | 87 | 93 |
Price vs. Book (P/B)
|
6 | 1 | 1 | 1 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
16 | 10 | 42 | 37 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
84 | 63 | 48 | 43 |
Profit Growth
|
9 | 98 | 21 | 98 |
Capital Growth
|
15 | 34 | 25 | 29 |
Stock Returns
|
89 | 91 | 61 | 43 |
Growth
|
59 | 97 | 25 | 61 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
71 | 46 | 100 | 100 |
Refinancing
|
9 | 6 | 1 | 7 |
Liquidity
|
98 | 8 | 80 | 80 |
|
86 | 1 | 100 | 100 |
Discover high‑ranked alternatives to Champions Oncology and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.